Famotidine
For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.
Active substance: Famotidine
Examples of brand names: Pepcid [USA]
ATC code: A02BA03
Main use (for orientation): Reflux; ulcer
Documented research summary
Within the documented search scope, no sufficiently attributable cannabinoid pair is established for Famotidine. The structured assessment distinguishes documented drug context from the absence of specific interaction evidence. Missing data do not establish safety.
Uncertainties and limitations
Transporter and enzyme context does not provide clinical CBD/THC effect sizes. Do not independently change prescribed medicines on the basis of this research dataset.
Structured assessment
Category: Drug context
Cannabinoid scope: No specifically substantiated pair involving a registered cannabinoid in the material assessed; no claim that all 28 cannabinoids were comprehensively reviewed simultaneously.
Evidence status: Drug properties supported by product information; insufficient evidence for a specific cannabinoid–drug pair effect.
Mechanism / drug context: Predominantly renal elimination; transporter involvement and weak CYP1A2 inhibition in the selected information.
Type of supporting material: Product information and documented individual literature screening; no clinical pair trial approved for use as evidence.
Clinical interpretation: No reliable cannabinoid–famotidine effect.
Context: Famotidine and cimetidine, with its much broader enzyme inhibition, are not interchangeable.
Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.
Source role [VD_LABEL_D0272]: Original product information: drug context, not evidence for a cannabinoid–drug pair
Statement supported: Predominantly renal elimination; transporter involvement and weak CYP1A2 inhibition in the selected information.
Source: Famotidine oral tablets – DailyMed SPL [VD_LABEL_D0272]
Source role [VE_LABEL_D0273]: Documented research / scope-distinction context; no cannabinoid–drug pair evidence approved for use
Statement supported: Famotidine and cimetidine, with its much broader enzyme inhibition, are not interchangeable.
Source: CIMETIDINE TABLET, FILM COATED [TEVA PHARMACEUTICALS USA, INC.] [VE_LABEL_D0273]
Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.
Unresolved source question: All individual review fields read. Original product information was rechecked only in the relevant pharmacokinetic/interaction excerpts; no complete recertification of all labels or worldwide full-text search. Literature access was based on the previously documented review; only the listed web sources were additionally read in this round. Transporter and enzyme context does not provide clinical CBD/THC effect sizes.
Separately recorded findings
No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.
References and access status
[VD_LABEL_D0272] Famotidine oral tablets – DailyMed SPL
Original source / bibliographic reference
Authors: Marketing authorisation holder / label provider according to the linked DailyMed product information
Year: 2024
Source type: Regulatory product information (US SPL)
Source access – 23 October 2026: Source destination was accessible when checked.
Bibliographic attribution or source identity cross-checked.
[VE_LABEL_D0273] CIMETIDINE TABLET, FILM COATED [TEVA PHARMACEUTICALS USA, INC.]
Original source / bibliographic reference
Authors: Respective marketing authorisation holder; regulatory product information
Year: 2022
Source type: Product information / SmPC / US Prescribing Information
Source access – 23 October 2026: Source destination was accessible when checked.
Bibliographic attribution or source identity cross-checked.
Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.
Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility
Famotidine and cannabinoids: documented findings, evidence, sources and data gaps. Research information for discussion with your doctor or pharmacist.